Dr. Borgen on the Decision to be Tested for a BRCA Gene
Patrick Borgen, MD
Published Online: Thursday, May 23, 2013
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.
Borgen says that testing for a BRCA gene can have profound impact on individuals and families and that the decision to be tested should remain up to the patient.
While few women regret having a prophylactic or risk-reducing mastectomy, some do. These women who regret the procedure, Borgen says, are often those who are talked into it by their physician. The physician's job is to inform a patient about the costs and benefits of the procedure and let them make the decision.
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression